Overview
Merck & Co., headquartered in Rahway, New Jersey, provides prescription medicines, vaccines, biologic therapies and animal-health products,.[2] Forbes records sales of US$65.5bn and profit of US$8.9bn, with a market value of US$275.1bn.[2] Its reporting is split into a Pharmaceutical segment covering human medicines and vaccines, an Animal Health segment for livestock and companion animals, and a residual Other segment.[2] In October 2025 Merck completed the purchase of Verona Pharma for US$107 per American depositary share, a transaction valued at about US$10bn, gaining Ohtuvayre (ensifentrine), a maintenance treatment for chronic obstructive pulmonary disease.[5] Sales grew 2.8% against the prior-year figure, slower than most peers, and the company slipped from third to fourth place as Lilly overtook it.[2] It is a separate company from Merck KGaA of Darmstadt, which ranks seventeenth.
Merck & Co. strengths and limitations
Strengths
- Fourth-largest sales in the industry
- Animal-health arm diversifies revenue
- Added a respiratory product through the Verona deal
Limitations
- Sales growth of 2.8% trailed most peers
- Shares its name with the unrelated Merck KGaA
- Acquisitions add amortisation charges
Appears in
Merck & Co. peers and competitors
Companies ranked in the same lists as Merck & Co..
Johnson & Johnson
Takeda Pharmaceutical
Daiichi Sankyo- Astellas Pharma
Viatris- Regeneron Pharmaceuticals
- CSL
Otsuka Holdings- Teva Pharmaceutical
Merck KGaA
Gilead Sciences- Amgen
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.